Loading...
•
Dec 31, 2019
Scholar Rock Q4 2019 Earnings Report
Scholar Rock reported financial results for the full year ended December 31, 2019 and highlighted recent progress and upcoming milestones for its pipeline programs.
Key Takeaways
Scholar Rock reported a net loss of $51.0 million for the year ended December 31, 2019. The company's cash, cash equivalents, and marketable securities totaled $157.4 million as of December 31, 2019.
Initiated the Phase 1 proof-of-concept clinical trial of SRK-181 in patients with locally advanced or metastatic solid tumors.
On track to report interim safety and efficacy data from the TOPAZ Phase 2 clinical trial of SRK-015 in patients with Type 2 and Type 3 Spinal Muscular Atrophy in mid-2020.
Achieved First Milestone of $25 Million in Strategic Fibrosis Collaboration with Gilead Sciences.
A $25 million payment was received in January 2020 from Gilead for the achievement of the preclinical milestone under the strategic fibrosis-focused collaboration.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...